Main menu

Drug Safety

drug-safety

Pfizer's Drug Safety R&D group develops and applies the skills, experience and scientific tools necessary for safety assessment and risk management of targets and compounds across the research, development and commercial phases of drug development. We seek to enhance our capabilities for target safety assessment, selection of safer compounds, toxicity risk management and translation of preclinical models.

WRD is interested in establishing alliances to develop and access:

  • Mechanisms, biomarkers, and screening approaches related to target organ toxicity
    • Cardiovascular safety
    • Liver injury
    • Hypersensitivity
    • Nephrotoxicity — esp., glomerular
    • Skeletal and cardiac muscle toxicity
    • Ocular safety
    • Screening for abuse potential
  • Biotherapeutics
    • Immunogenicity and other safety relevant assays
  • Deeper knowledge of targets and pathways
    • Knock-in, knock-out technologies
    • Humanized animal models
    • Novel technologies and increased throughput for target localization studies
  • Safety Biomarker Technologies
    • Platforms; multiplex; analytical approaches; validated reagents

Not actively seeking partnering opportunities in:

  • Genetox Screening
  • hERG related assays
  • In vitro screening models without significant validation
  • In silico approaches without experimental validation

R & D Brochure

callout-placeholder

Understand what R&D is looking for in an early stage opportunity.

 

Connect With Us

callout-placeholder

Reach out. We want to hear from you.